Modern (MRNA) – Report from Moderna, Inc. to pick up shares fell lower Monday as Pfizer (PFE) – Pfizer Inc. Report Received came into the red as investors reacted to the general risk associated with drug makers’ coronavirus vaccines in the Asia-Pacific region.
Japan suspended a new batch of Moderna vaccines on Sunday after the discovery of contaminants in vials near the capital Tokyo. Authorities have collected a total of more than 2.6 million Moderna vaccine doses, but have indicated that as many as 500,000 people could have received shots from potentially contaminated stocks.
The news comes as Japan continues to grapple with the latest coronavirus wave, with monthly infections crossing 25,000 for the first time as the Delta variant continues to accelerate in the Asian region.
Moderna said earlier this week that the contamination could come from the manufacturing sites of its Spanish partner, Rovi, which bottles the vaccine for non-U.S. markets.
Meanwhile, reports in New Zealand suggest one person has died as a result of a myocarditis-linked Pfizer’s recently approved “Comiranty” COVID vaccine.
Moderna shares were marked 2.4% lower in pre-market trading Monday to mark an opening bell price of $373.00 apiece, a move that would still leave the stock with the year’s best profit to date up from the S&P 500 by about 245%.
Pfizer shares, meanwhile, rose 0.9% lower to indicate an opening bell price of $46.20 apiece.
Last week, the U.S. Food & Drug Administration gave its formal approval for the drugmaker’s coronavirus vaccine in a move that marked the agency’s first full authorization since it granted emergency use authorization late last year.
The FDA said the vaccine, which Pfizer produces with its German partner BioNTech, BNTX, is now available for sale at “Comiranty” and will be eligible for use by all US citizens over the age of 16.
Last month, Pfizer said sales of its vaccine, which was first labeled as BNT162b2 when it received emergency use approval late last year, could reach $33.5 billion this year as it pushed its 2021 profit forecast to between $4 billion. 3.95 and $4.05 per share.